UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

~~December~~January 1020, ~~2025~~2026

Date of Report (Date of earliest event reported):

AYTU BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38247		47-0883144
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7900 East Union Avenue, Suite 920

Denver, CO 80237

(Address of principal executive offices, including zip code)

(720) 437-6580

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		AYTU		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 57.0701 ~~Submission~~Regulation ofFD ~~Matters to a Vote of Security Holders~~Disclosure.

On ~~December~~January 1020, ~~2025~~2026, Aytu BioPharma, Inc. (the “Company”) ~~held~~or ~~its 2026 annual meeting of stockholders (~~“~~2026 Annual Meeting~~Aytu”)~~. At~~ ~~the~~issued ~~close~~a ofpress ~~business~~release ontitled ~~October~~“Aytu ~~13,~~BioPharma ~~2025,~~Recaps ~~the~~Investor ~~record~~Day ~~date~~Held ~~for~~on ~~the~~January ~~2026 Annual Meeting~~20, ~~there~~2026.” ~~were~~A ~~10,188,208~~copy ~~shares~~ of the ~~Company’s~~press ~~common~~release ~~stock~~is ~~issued~~furnished ~~and outstanding with each share being entitled to one vote and to be voted together~~ as ~~one~~Exhibit ~~class at the 2026 Annual Meeting~~99.1 ~~At the 2026 Annual Meeting, there were present in person or by proxy 6,083,713 shares of the Company’s common stock, representing stockholders entitled~~ to ~~vote~~this ofCurrent ~~approximately~~Report ~~60% of the total issued and outstanding~~ on ~~the~~Form ~~record date and constituting a quorum~~8-K.

~~Set~~On ~~forth~~January 20, ~~below~~2026, ~~are~~ the ~~voting~~Company ~~results~~posted ~~for~~to ~~the~~its ~~three~~website a ~~proposals~~presentation ~~considered~~that ~~and~~was used ~~voted~~in ~~upon~~connection atwith ~~the~~an ~~2026 Annual~~investor ~~Meeting~~meeting held on January 20, ~~all~~2026. ofThe ~~which~~presentation ~~were~~includes, ~~described~~among inother matters, information on the ~~Company’s Definitive~~EXXUA™ ~~Proxy~~(gepirone) ~~Statement~~extended-release ontablets ~~Schedule~~opportunity. ~~14A~~A ~~filed~~copy ~~with~~of the ~~United~~presentation ~~States~~is ~~Securities~~attached ~~and~~hereto ~~Exchange~~as ~~Commission~~Exhibit on99.2 to ~~October~~this ~~24,~~Current Report on Form ~~2025~~8-K. The presentation can also be viewed on the Company’s website at https://investors.aytubio.com/ under Events & Presentations.

~~Proposal~~The ~~No.~~information in the press release attached as Exhibit 99.1 -and ~~Election~~the information in the presentation attached as Exhibit 99.2 hereto shall not be deemed to be “filed” for purposes of ~~Directors~~Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

~~The~~Item ~~Company’s stockholders elected all of the incumbent directors that stood for reelection~~9.01 ~~Each~~Financial ~~director~~Statements ~~was elected by a majority vote. The directors elected~~ and ~~the final vote tabulation for each director is as follows:~~Exhibits.

Director	Votes Cast For		Votes Withheld		Broker Non-Votes
Joshua R. Disbrow		3,192,818		351,123		2,539,772
John A. Donofrio, Jr.		3,269,350		274,591		2,539,772
Carl C. Dockery		3,210,190		333,751		2,539,772
Abhinav “Abi” Jain		3,455,220		88,721		2,539,772
Vivian H. Liu		3,454,342		89,599		2,539,772

(d) Exhibits.

Proposal No. 2 - Appointment of Independent Registered Public Accounting Firm

Exhibit Number		Exhibit Description
99.1		Press Release dated January 20, 2026
99.2		Investor Day Presentation Dated January 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

The Company’s stockholders approved the proposal to ratify the appointment by the Company’s Audit Committee of Grant Thornton LLP, as the Company’s independent registered public accounting firm for the fiscal year ended June 30, 2026. The final vote tabulation for this proposal is as follows:

Votes Cast For		Votes Cast Against		Votes Cast Abstain		Broker Non-Votes
5,783,905		257,411		42,397		─

Proposal No. 3 - Advisory Vote on Executive Compensation

The Company’s stockholders approved, by a non-binding advisory vote, the proposal regarding executive compensation. The final vote tabulation for this proposal is as follows:

Votes Cast For		Votes Cast Against		Votes Cast Abstain		Broker Non-Votes
3,193,511		311,200		39,230		2,539,772

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AYTU BIOPHARMA, INC.
Date: December 10, 2025	By:	/s/ Ryan J. Selhorn
Date: January 20, 2026	By:	/s/ Ryan J. Selhorn
		Ryan J. Selhorn
		Chief Financial Officer

Filing Compare · AYTU BIOPHARMA, INC